How genetics and the immune system affect sacituzumab plus radiation for bladder cancer
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
This work looks at whether adding the antibody-drug sacituzumab to radiation helps people with muscle-invasive bladder cancer and which genetic or immune factors change that response.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11135444 on NIH RePORTER |
What this research studies
If you take part, researchers will collect tumor and blood samples from people with muscle-invasive bladder cancer who receive radiation combined with either sacituzumab or standard cisplatin-based therapy. They will analyze tumor genes, immune cells around the tumor, and markers of treatment response to find patterns linked to benefit or resistance. Laboratory studies will connect those patient samples to how tumors respond to radiation plus the drug. The team aims to link specific genetic changes and immune features to who does well or poorly with each treatment approach.
Who could benefit from this research
Good fit: Adults with muscle-invasive bladder cancer who are candidates for radiation-based, bladder-sparing treatment are the most relevant participants.
Not a fit: People with non–muscle-invasive bladder cancer, cancers outside the bladder, or who will not receive radiation are unlikely to be included or directly helped by this work.
Why it matters
Potential benefit: This could help doctors predict who is most likely to benefit from sacituzumab plus radiation and lead to more personalized treatments that improve bladder preservation and survival.
How similar studies have performed: Antibody-drug conjugates like sacituzumab have shown activity in bladder cancer, but combining them with radiation and tying responses to genetic and immune markers is a newer approach with promising but still limited prior data.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Chan, Timothy an-Thy — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Chan, Timothy an-Thy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.